Sabine D. Brookman-May/X
Nov 3, 2024, 09:32
Sabine D. Brookman-May: ESSA terminates Phase 2 trial
Sabine D. Brookman-May posted on X:
“ESSA terminates Phase 2 trial: masofaniten (Epi-7386/N-terminal AR antagonist) plus enzalutamide vs enza mono in mCRPC patients naïve to 2nd gen antiandrogens (+ other combination studies) At futility analysis higher rate of PSA90 with enza mono.”
Sabine D. Brookman-May is the Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences. Previously, she was the Vice President of Bladder Cancer Development, Research and Development at Janssen Pharmaceutical Companies of Johnson & Johnson. She also serves as a professor of Urology at Ludwig Maximilian University of Munich, specializing in Urology, Oncology, and Sports and Exercise Medicine.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 19, 2024, 10:18
Nov 19, 2024, 10:05
Nov 19, 2024, 09:53
Nov 19, 2024, 09:44
Nov 19, 2024, 09:40
Nov 19, 2024, 09:28